Table 1.
Association between glycemic control and adverse cardiorenal outcomes in people with type 2 diabetes and chronic kidney disease
| HbA1c levels |
|||||
|---|---|---|---|---|---|
| <7% n= 10,709 (stage 3) n= 1072 (stage 4) |
Stage 3 CKD |
Stage 4 CKD |
|||
| 7%–9% n = 8060 |
>9% n = 2386 |
7%–9% n = 793 |
>9% n = 276 |
||
| All-cause mortality | 1 | 1.04 (0.96–1.13) |
1.35 (1.20–1.53) |
1.03 (0.87–1.21) |
1.39 (1.10–1.76) |
| All-cause hospitalization | 1 | 1.09 (1.04–1.15) |
1.44 (1.36–1.52) |
1.13 (1.02–1.25) |
1.25 (1.01–1.54) |
| Myocardial infarction | 1 | 1.33 (1.16–1.53) |
1.85 (1.53–2.25) |
1.35 (0.85–2.15) |
2.35 (1.32–4.18) |
| Stroke | 1 | 1.24 (1.05–1.46) |
1.96 (1.56–2.47) |
1.64 (1.00–2.71) |
1.20 (0.51–2.80) |
| Heart failure | 1 | 1.32 (1.18–1.48) |
1.89 (1.61–2.21) |
1.16 (0.89–1.52) |
1.32 (0.88–1.98) |
| ESRD | 1 | 1.22 (0.80–1.86) |
2.52 (1.58–4.02) |
1.03 (0.78–1.35) |
1.13 (0.80–1.59) |
| Doubling of serum creatinine level | 1 | 1.10 (0.95–1.26) |
1.77 (1.48–2.13) |
1.05 (0.78–1.41) |
1.40 (1.17–1.67) |
Notes: A total of 23,296 people with diabetes mellitus and an estimated glomerular filtration rate lower than 60 mL/min/1.73 m2 were identified within the Alberta Kidney Disease Network, Canada. Over the median follow-up period of 46 months, 3665 people died and 401 developed ESRD. The table highlights adjusted risk of adverse outcomes among people with stage 3 and stage 4 CKD, by baseline HbA1c.12
Abbreviations: CKD, chronic kidney disease: ESRD, end-stage renal disease: HbA1c, glycated hemoglobin.